Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 2/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 2/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.35 |
| ▸ | CPN1 | P15169 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19066729 | 1.00 | GRN (0.46) | GRNSORT1CTSSCTSKCPB2 | |
| SCHEMBL15764276 | 0.92 | GRN (0.44) | GRNSORT1CTSSCTSKCPB2 | |
| SCHEMBL22122370 | 0.92 | GRN (0.44) | GRNSORT1CTSSCTSKCPB2 | |
| SCHEMBL24965929 | 0.92 | GRN (0.48) | GRNSORT1CTSSCTSKCPB2 | |
| SCHEMBL5275514 | 0.92 | GRN (0.48) | GRNSORT1CTSSCTSKCPB2 | |
| SCHEMBL25357322 | 0.92 | GRN (0.44) | GRNSORT1CTSSCTSKCPB2 | |
| SCHEMBL19750968 | 0.90 | GRN (0.50) | GRNSORT1CTSSCTSKCPB2 | |
| SCHEMBL805198 | 0.90 | GRN (0.50) | GRNSORT1CTSSCTSKCPB2 | |
| SCHEMBL7571759 | 0.90 | GRN (0.50) | GRNSORT1CTSSCTSKCPB2 | |
| SCHEMBL7566961 | 0.90 | GRN (0.50) | GRNSORT1CTSSCTSKCPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612156-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-20 | — | — | US | disclosed |
| WO-2024097296-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-4216961-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CORONAVIRUS INFECTION | Lighthouse Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| CN-108699052-B | Anthelmintic depsipeptide compounds | 勃林格殷格翰动物保健美国公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3397638-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Merial, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| CN-108699052-A | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | 梅里亚股份有限公司 | 2018-10-23 | — | — | CN | disclosed |
| WO-2017116702-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL, INC. (US) | 2017-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | GRN 3398/4885SORT1 1183/4885CTSS 793/4885 |
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | GRN 1098/4885SORT1 3963/4885CTSS 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.